Bioatla Financials
| BCAB Stock | USD 0.33 0.02 4.94% |
Bioatla Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.42 | 3.17 |
|
|
Investors should never underestimate Bioatla's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bioatla's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bioatla.
Net Income |
|
Bioatla | Select Account or Indicator | Build AI portfolio with Bioatla Stock |
Understanding current and past Bioatla Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bioatla's financial statements are interrelated, with each one affecting the others. For example, an increase in Bioatla's assets may result in an increase in income on the income statement.
Please note, the presentation of Bioatla's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bioatla's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bioatla's management manipulating its earnings.
Bioatla Stock Summary
Bioatla competes with Celularity, PolyPid, Annovis Bio, Reviva Pharmaceuticals, and Evaxion Biotech. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US09077B1044 |
| Business Address | 11085 Torreyana Road, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bioatla.com |
| Phone | 858 558 0708 |
| Currency | USD - US Dollar |
Bioatla Key Financial Ratios
| Return On Equity | -8.14 | ||||
| Price To Sales | 4.22 X | ||||
| Revenue | 11 M | ||||
| Gross Profit | (46.73 M) | ||||
| EBITDA | (73.02 M) |
Bioatla Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 254.4M | 225.7M | 119.7M | 52.4M | 60.3M | 57.3M | |
| Other Current Liab | 17.2M | 17.4M | 22.9M | 11.8M | 13.6M | 15.2M | |
| Net Tangible Assets | (145.3M) | 210.0M | 210.8M | 180.3M | 207.4M | 217.8M | |
| Net Debt | (239.6M) | (211.5M) | (109.0M) | (48.2M) | (43.4M) | (45.6M) | |
| Retained Earnings | (186.3M) | (292.8M) | (416.3M) | (486.0M) | (437.4M) | (415.6M) | |
| Accounts Payable | 1.2M | 4.2M | 3.8M | 1.9M | 1.7M | 2.4M | |
| Cash | 245.0M | 215.5M | 111.5M | 49.0M | 56.4M | 53.6M | |
| Other Current Assets | 2.3M | 4.9M | 4.9M | 2.2M | 2.5M | 3.0M | |
| Total Liab | 43.6M | 45.4M | 49.0M | 38.2M | 34.3M | 36.7M | |
| Net Invested Capital | 210.8M | 180.3M | 70.7M | 14.3M | 16.4M | 15.6M | |
| Total Current Assets | 247.3M | 220.4M | 116.4M | 51.2M | 58.9M | 56.0M | |
| Capital Stock | 3K | 4K | 5K | 6K | 5.4K | 5.1K | |
| Net Working Capital | 227.5M | 197.3M | 88.1M | 36.7M | 42.2M | 40.1M | |
| Common Stock | 3K | 4K | 5K | 6K | 5.4K | 5.1K | |
| Short Term Debt | 1.4M | 1.5M | 1.6M | 836K | 752.4K | 714.8K |
Bioatla Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Net Interest Income | 347K | 1.6M | 5.7M | 3.4M | 3.9M | 4.1M | |
| Interest Income | 350K | 1.6M | 5.7M | 3.4M | 3.9M | 4.1M | |
| Interest Expense | 1.6M | 1.4M | 3K | 1.7M | 1.5M | 900.6K | |
| Total Revenue | 429K | 250K | 0.0 | 11M | 9.9M | 10.4M | |
| Gross Profit | 250K | (1.2M) | (1.2M) | 10.1M | 11.6M | 12.2M | |
| Operating Income | (96.4M) | (108.1M) | (129.7M) | (73.9M) | (66.5M) | (69.9M) | |
| Ebit | (95.4M) | (106.5M) | (123.5M) | (73.9M) | (66.5M) | (69.9M) | |
| Research Development | 58.3M | 79.3M | 103.7M | 63.1M | 72.6M | 59.2M | |
| Ebitda | (94.1M) | (105.3M) | (122.2M) | (73.0M) | (65.7M) | (69.0M) | |
| Cost Of Revenue | 1.3M | 1.2M | 1.2M | 925K | 832.5K | 790.9K | |
| Income Before Tax | (95.4M) | (106.5M) | (123.5M) | (69.8M) | (62.8M) | (65.9M) | |
| Net Income | (95.4M) | (105.3M) | (123.5M) | (69.8M) | (62.8M) | (65.9M) | |
| Income Tax Expense | 1.5M | 1.4M | 4K | (1.2M) | (1.1M) | (1.0M) |
Bioatla Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (1.5M) | (590K) | (924K) | (265K) | (121K) | 0.0 | |
| Change In Cash | 6.4M | (29.5M) | (104.0M) | (62.4M) | (56.2M) | (53.4M) | |
| Free Cash Flow | (63.1M) | (90.7M) | (104.1M) | (71.9M) | (64.7M) | (68.0M) | |
| Depreciation | 1.3M | 1.2M | 1.2M | 925K | 1.1M | 1.2M | |
| Other Non Cash Items | 3K | 13K | 2K | (807K) | (928.1K) | (974.5K) | |
| Capital Expenditures | 1.5M | 590K | 924K | 268K | 98K | 0.0 | |
| Net Income | (95.4M) | (106.5M) | (123.5M) | (69.8M) | (62.8M) | (65.9M) | |
| End Period Cash Flow | 245.0M | 215.5M | 111.5M | 49.0M | 56.4M | 53.6M | |
| Change To Netincome | (5.8M) | 1.0M | 24.4M | 14.6M | 16.8M | 17.6M |
Bioatla Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bioatla's current stock value. Our valuation model uses many indicators to compare Bioatla value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bioatla competition to find correlations between indicators driving Bioatla's intrinsic value. More Info.Bioatla is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Bioatla's Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bioatla's earnings, one of the primary drivers of an investment's value.Most indicators from Bioatla's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bioatla current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.At present, Bioatla's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.25, whereas Selling General Administrative is forecasted to decline to about 22.9 M.
| 2023 | 2024 | 2025 | 2026 (projected) | Depreciation And Amortization | 1.2M | 925K | 1.1M | 1.2M | Interest Income | 5.7M | 3.4M | 3.9M | 4.1M |
Bioatla fundamental ratios Correlations
Click cells to compare fundamentals
Bioatla Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bioatla fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 254.4M | 225.7M | 119.7M | 52.4M | 60.3M | 57.3M | |
| Other Current Liab | 17.2M | 17.4M | 22.9M | 11.8M | 13.6M | 15.2M | |
| Net Tangible Assets | (145.3M) | 210.0M | 210.8M | 180.3M | 207.4M | 217.8M | |
| Net Debt | (239.6M) | (211.5M) | (109.0M) | (48.2M) | (43.4M) | (45.6M) | |
| Retained Earnings | (186.3M) | (292.8M) | (416.3M) | (486.0M) | (437.4M) | (415.6M) | |
| Accounts Payable | 1.2M | 4.2M | 3.8M | 1.9M | 1.7M | 2.4M | |
| Cash | 245.0M | 215.5M | 111.5M | 49.0M | 56.4M | 53.6M | |
| Other Current Assets | 2.3M | 4.9M | 4.9M | 2.2M | 2.5M | 3.0M | |
| Total Liab | 43.6M | 45.4M | 49.0M | 38.2M | 34.3M | 36.7M | |
| Net Invested Capital | 210.8M | 180.3M | 70.7M | 14.3M | 16.4M | 15.6M | |
| Total Current Assets | 247.3M | 220.4M | 116.4M | 51.2M | 58.9M | 56.0M | |
| Capital Stock | 3K | 4K | 5K | 6K | 5.4K | 5.1K | |
| Net Working Capital | 227.5M | 197.3M | 88.1M | 36.7M | 42.2M | 40.1M | |
| Common Stock | 3K | 4K | 5K | 6K | 5.4K | 5.1K | |
| Short Term Debt | 1.4M | 1.5M | 1.6M | 836K | 752.4K | 714.8K |
Today, most investors in Bioatla Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bioatla's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bioatla growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Bioatla January 26, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bioatla help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bioatla. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bioatla based on widely used predictive technical indicators. In general, we focus on analyzing Bioatla Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bioatla's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 54.11 | |||
| Value At Risk | (16.25) | |||
| Potential Upside | 15.28 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |